期刊文献+

曲古菌素A诱导淋巴瘤Raji细胞表达共刺激分子CD80及CD86的表达

Expression of costimulatory molecule CD80 and CD86 in Raji cells induced by trichostatin A
下载PDF
导出
摘要 目的探讨组蛋白去乙酰化酶抑制剂曲古菌素A(TSA)诱导淋巴瘤细胞Raji细胞表达共刺激分子CD80和CD86及其与免疫应答的关系。方法采用MTT法和倒置相差显微镜观察不同浓度TSA对Raji细胞的抑制作用,流式细胞仪检测150 nmol/L TSA作用Raji细胞后的细胞表达共刺激分子CD80和CD86及细胞活力,RT-PCR分析CD80 mRNA和CD86 mRNA表达情况。结果 TSA对Raji细胞的抑制作用具有时间和剂量依赖性,150 nmol/L TSA作用后可上调Raji细胞表达CD80,并对Raji细胞有直接杀灭作用。结论 TSA可以诱导Raji细胞表达共刺激分子CD80,不表达CD86,促进细胞的免疫应答,为抗恶性血液病提供了一个新的免疫治疗方法。 Objective To explore the expression of costimulatory molecule CD80 and CD86 in myeloid lymphoma Raji cells induced by histone deacetylase inhibitors trichostatin A( TSA) as well as its relationship with immune response. Methods The proliferative activity of Raji cells was assessed by morphology and M TT assay. The expression of CD80 and CD86 was confirmed,and cells viability was examined by FlowCytometer after managing Raji cells with 150 nmol / L TSA. The expression status of CD80 and CD86 mRNA was analyzed by RT-PCR. Results A timeand dose-dependent inhibition was detected in Raji cells treated with TSA. After TSA( 150 nmol / L) treatment,the expression of CD80 was up-regulatied in Raji cells. Raji cells were directly killed. Conclusion TSA can induce costimulatory molecular CD80 expression of Raji cells,improve immune response of cells,and provide a novel immunotherapy for fighting against lymphoma disease.
出处 《实用药物与临床》 CAS 2016年第3期261-264,共4页 Practical Pharmacy and Clinical Remedies
基金 湖北省教育厅基金资助项目(530026) 江西省自然科学基金资助项目(0640190) 武汉科技大学专项基金资助项目(zx0802)
关键词 曲古菌素A CD80 CD86 免疫应答 Trichostatin A CD80 CD86 Immune response
  • 相关文献

参考文献20

  • 1Marks P,Rifkind RA,Richon VM,et al.Histone deacety lases and cancer:causes and therapies[J].Nat Rev Cancer,2001,1(3):194-202.
  • 2Kwon HJ,Kim M,Kim DH.Histone deacetylase in carcinogenesis and its inhibitor as anti-cancer agents[J].J Biochem M ol Biol,2003,36(1):110-119.
  • 3Lenschow DJ,Walunas TL,Bluestone JA.CD28/B7 system of T cell costimulation[J].Annu Rev Immunol,1996,14:233-258.
  • 4Khan AN,Magner WJ,Tomasi TB.An epigenetically altered tumor cell vaccine[J].Concer Immunol Immunother,2004,53(8):749-754.
  • 5Lemal R,Ravinet A,Molucon-Chabrot C,et al.Histone deacetylase inhibitors in the treatment of hematological malignancies[J].Bull Cancer,2011,98(8):867-878.
  • 6Foglietta F,Serpe L,Canaparo R,et al.Modulation of butyrate anticancer activity by solid lipid nanoparticle delivery:an in vitro investigation on human breast cancer and leukemia cell lines[J].J Pharm Sci,2014,17(2):231-247.
  • 7Peiffer L,Poll-Wolbeck SJ,Flamme H,et al.Trichostatin A effectively induces apoptosis in chronic lymphocytic leukemia cells via inhibition of Wnt signaling and histone deacetylation[J].J Cancer Res Clin Oncol,2014,140(8):1283-1293.
  • 8Merezak C,Reichert M,Van Lint C,et al.Inhibition of histone deacetylases induces bovine leukemia virus expression in vitro and in vivo[J].J Virol,2002,76(10):5034-5042.
  • 9Kanno S,Maeda N,Tomizawa A,et al.Characterization of cells resistant to the potent histone deacetylase inhibitor spiruchostatin B(SP-B)and effect of overexpressed p21w af1/cip1on the SP-B resistance or susceptibility of human leukemia cells[J].Int J Oncol,2012,41(3):862-868.
  • 10D'Amato L,Dell'Aversana C,Conte M,et al.ARHGEF3 controls HDACi-induced differentiation via Rho A-dependent pathw ays in acute myeloid leukemias[J].Epigenetics,2015,10(1):6-18.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部